Bethelview Pharmacy

Peptides are coming to Bethelview Pharmacy: what the new HHS policy means for Cumming patients

Peptides are coming to Bethelview Pharmacy: what the new HHS policy means for Cumming patients

Peptide compounding just changed in a big way. On October 28, 2026, the U.S. Department of Health and Human Services (HHS) announced a draft policy saying it does not intend to take enforcement action against state-licensed pharmacies that compound six peptides, including BPC-157, TB-500, KPV and MOTS-c, as long as 10 strict conditions are met.

For patients, that means these peptides can now be prepared by a licensed pharmacy, on a prescription, with sourcing, testing and safety reporting rules attached. That is a very different path from the “research use only” vials sold online.

At Bethelview Pharmacy in Cumming, GA, owner and pharmacist Kevin Patel, PharmD, RPh, and our team are preparing to compound BPC-157, TB-500, KPV and MOTS-c under this policy. This guide explains what the new policy says, what it does not say, which forms are allowed, what the research shows so far, and what the process will look like for patients and providers across Forsyth County.

Key takeaways

  • A new federal pathway: HHS issued a draft enforcement discretion policy on October 28, 2026, published in the Federal Register on October 30, 2026, covering six peptides: BPC-157, TB-500, KPV, MOTS-c, Semax and Epitalon.
  • Not FDA approval: The policy does not approve any peptide and does not add any peptide to the FDA’s 503A bulks list. Compounded peptides remain unapproved drugs.
  • Prescription required: Every compounded peptide must be based on a valid, patient-specific prescription from a licensed provider.
  • One peptide per product: Each compounded product may contain only one active ingredient, so blends and “stacks” are not allowed under the policy.
  • Specific forms only: KPV is limited to oral and topical forms. TB-500 and MOTS-c are limited to injections. BPC-157 is allowed as an injection, oral or topical form.
  • Strict sourcing rules: Ingredients must come from FDA-registered facilities with a valid certificate of analysis covering identity, purity and contaminants.
  • The research is still early: Most evidence for these peptides comes from animal and lab studies. FDA reviewers recommended against listing all four.
  • The rules may change: Public comments close November 13, 2026, and HHS can revise or withdraw the policy.

Want to know when peptide compounding is available at Bethelview Pharmacy? Let us know you are interested and we will keep you updated. Contact our pharmacist team.

What did HHS announce about compounded peptides?

HHS announced a draft “enforcement discretion” policy for six peptides used in pharmacy compounding. In plain terms, HHS said it does not plan to take action against state-licensed pharmacies, federal facilities or licensed physicians that compound these peptides, as long as every one of the policy’s 10 conditions is met.

The notice was signed by HHS Secretary Robert F. Kennedy Jr. and published in the Federal Register on October 30, 2026 (91 Fed. Reg. 68526). Notably, HHS issued the policy itself rather than the U.S. Food and Drug Administration (FDA).

HHS gave two reasons for the policy, according to Arnold & Porter’s legal summary:

  • Expanding patient access to peptides for which no FDA-approved product exists.
  • Steering people away from “research use only” peptides made by foreign manufacturers, which HHS described as a safety risk to U.S. patients.

The policy covers 503A pharmacies only. These are traditional, state-licensed compounding pharmacies like Bethelview Pharmacy that prepare medications for individual patients. It does not cover 503B outsourcing facilities that make larger batches for clinics.

The National Community Pharmacists Association (NCPA) told its members that 503A pharmacies may compound the six peptides under the policy’s conditions. Public comments on the draft are due by November 13, 2026.

Which peptides will Bethelview Pharmacy compound, and in what forms?

Bethelview Pharmacy is preparing to compound four of the six peptides covered by the policy: BPC-157, TB-500, KPV and MOTS-c. The policy does not let a pharmacy choose any form it likes. Appendix B of the HHS policy lists the exact identity and route of administration allowed for each peptide.

Peptide What it is Forms allowed under the HHS policy Where the research stands
BPC-157 acetate A 15 amino acid synthetic peptide based on a protein found in gastric juice Injection (under the skin or into the muscle), oral, topical Mostly animal studies, with a few small human reports
TB-500 acetate A short synthetic fragment of thymosin beta-4, a natural protein Injection (under the skin or into the muscle) No published human data identified by FDA
KPV acetate A 3 amino acid fragment of the hormone alpha-MSH Oral and topical only Animal and lab studies only
MOTS-c acetate A 16 amino acid peptide encoded in mitochondrial DNA Injection (under the skin or into the muscle) Animal studies; no human dosing data identified by FDA
Sources: HHS Appendix B, GoodRx Peptide Watch, reviewed October 28, 2026, FDA PCAC peptide evaluations. Two details matter here. First, injectable KPV is not covered by the policy. Second, if any peptide is compounded in an oral form, the pharmacy must keep documentation showing that the specific formulation is adequately absorbed when taken by mouth. Your provider will decide which form, if any, fits your treatment plan. You can learn more about how custom medications are prepared on our compounding services page.

How did the rules on peptide compounding change?

From 2023 until April 2026, BPC-157, TB-500, KPV and MOTS-c sat on an FDA list of bulk substances that “may present significant safety risks,” which effectively kept pharmacies from compounding them. Three steps in 2026 changed that: the substances came off that list, an FDA advisory committee voted in their favor, and HHS issued its draft policy.

Date What happened What it meant
2023 FDA placed these peptides in Category 2 of its interim 503A bulks policy Compounding was effectively off-limits
April 2026 The peptide nominations were withdrawn, removing them from Category 2 Off the "do not compound" list, but still not eligible
June 2026 FDA staff briefing documents recommended against adding any of the seven reviewed peptides FDA scientists remained opposed
July 23 to 24, 2026 The FDA's Pharmacy Compounding Advisory Committee (PCAC) voted to recommend six peptides, including all four Bethelview plans to compound An advisory vote only, not a change in law
October 14, 2026 An interim access policy was sent to the White House Office of Management and Budget for review The final step before release
October 28 to 30, 2026 HHS announced and published its draft enforcement discretion policy Pharmacies may compound under 10 conditions
November 13, 2026 Public comment deadline on the draft policy The policy could still be revised
February 2027 PCAC is scheduled to review five more peptides, including GHK-Cu Possible future additions

The PCAC votes were close. ABC News reported that the advisers narrowly backed the peptides, with supporters pointing to existing demand and the chance to move use out of the gray market and into regulated pharmacies.

You may have seen claims online that these peptides were “moved to Category 1” or “approved” earlier in 2026. Those claims are not accurate. The timeline above reflects what FDA and HHS actually published.

Does this mean peptides are FDA-approved?

No. The HHS policy does not approve BPC-157, TB-500, KPV or MOTS-c, and it does not add them to the FDA’s 503A bulks list. HHS itself acknowledges that compounded drugs are not FDA-approved and that FDA does not review their safety, effectiveness or quality before they reach patients.

Enforcement discretion is a decision not to take action under certain conditions. It is not a legal authorization. As Arnold & Porter explains, it does not change the Federal Food, Drug, and Cosmetic Act, does not bind state boards of pharmacy, and can be withdrawn without a formal rulemaking process.

What the HHS policy does What the HHS policy does not do
Lets 503A pharmacies compound six listed peptides under 10 conditions Approve any peptide as safe or effective
Requires a patient-specific prescription Allow purchase without a prescription
Sets sourcing, testing and labeling rules for the ingredients Add the peptides to the 503A bulks list
Requires reporting of serious adverse events to FDA MedWatch Cover 503B outsourcing facilities or office stock
Stays in place until FDA finishes rulemaking on each peptide Override state pharmacy laws
Gives a controlled alternative to research-use-only products Allow blends, stacks or forms outside Appendix B

The policy has no fixed end date. It remains in effect until each peptide is addressed in a final FDA rule, a process that could take an uncertain number of years. HHS may also revisit it if safety or quality concerns appear.

Have questions about what the new policy means for you? Our pharmacist team is happy to talk it through. Contact our pharmacist team.

How are pharmacy-compounded peptides different from "research use only" vials?

The main difference is accountability. A pharmacy-compounded peptide under the HHS policy starts with a prescription, uses an ingredient from an FDA-registered source with a certificate of analysis, is prepared by a licensed pharmacist, and comes with adverse event reporting. A “research use only” vial bought online has none of those guardrails.

FDA has made clear that a “research use only” label is not a legal shield. In August 2026, FDA’s drug center issued warning letters to online peptide sellers and rejected their research-use disclaimers because their marketing showed the products were meant for people.

Quality is also a real concern. A 2026 preprint analysis of independently tested peptide samples reported that a large share failed basic quality criteria and that measurable endotoxin contamination appeared in about 15% of samples. This study has not yet been peer reviewed, but it matches the concerns FDA reviewers raised about poorly characterized ingredients.

Factor Pharmacy-compounded peptide (HHS policy) "Research use only" vial
Prescription Required, patient-specific None
Who prepares it A state-licensed pharmacy Unknown manufacturer, often overseas
Ingredient source FDA-registered facility, cGMP-compliant manufacturer Not verified
Certificate of analysis Required, covering identity, purity, endotoxins, heavy metals and microbes Sometimes provided by the seller, not verified
Ingredients per product One active peptide only Blends and stacks common
Labeling "This is a compounded drug product. Not for resale." "Not for human consumption"
Adverse event reporting Serious events reported to FDA MedWatch and the state None
Pharmacist counseling Available None

Pharmacy compounding is more controlled, but it is not the same as FDA approval. Compounded peptides are still unapproved drugs, and that is why the provider’s evaluation and the pharmacist’s review both matter.

What are the 10 conditions pharmacies must meet?

The HHS policy only protects pharmacies that meet all 10 conditions at once. Several of them protect patients directly, from how the ingredient is sourced to how a side effect gets reported. Here is what each condition means in plain language, based on Arnold & Porter’s summary of the policy.

  1. Listed peptides only. The pharmacy may only use the six peptides listed in Appendix A of the policy.
  2. Correct identity and route. Each peptide must match the exact chemical identity and route of administration listed in Appendix B.
  3. Verified ingredient quality. The bulk peptide must come from an FDA-registered facility with a valid certificate of analysis showing identity, purity, potency, and testing for endotoxins, heavy metals, microbes and impurities.
  4. Known original manufacturer. The original manufacturer must be FDA-registered and follow current good manufacturing practice, and its facility location must be on the certificate of analysis.
  5. Safety reporting. Serious adverse events and product quality problems must be reported to FDA’s MedWatch program and to the states involved, with reporting instructions on the patient label.
  6. Clear labeling. The label must state: “This is a compounded drug product. Not for resale.”
  7. One active ingredient. Each product may contain only one peptide, which makes it easier to link any side effect to a specific substance.
  8. Proof for oral forms. For oral products, the pharmacy must keep documentation that the formulation is adequately absorbed in humans.
  9. Approved syringes only. The only delivery device included may be an FDA 510(k)-cleared syringe.
  10. All other federal rules apply. The product must be compounded in sanitary conditions and based on a valid, patient-specific prescription.

For patients, these conditions answer the most important questions you should ask any pharmacy: where did the ingredient come from, how was it tested, and what happens if something goes wrong?

We follow the same careful approach with our other compounded medications. Bethelview Pharmacy sources active ingredients from FDA-registered vendors and meets or exceeds USP 797 sterile compounding standards, as described on our weight management and GLP-1 page.

What does the research say about these peptides so far?

The honest answer is that the research on BPC-157, TB-500, KPV and MOTS-c is still early. Most studies have been done in animals or in the lab, and FDA’s own reviewers recommended against adding any of these four peptides to the bulks list because of limited human data and unanswered safety questions. We think you deserve to know that before talking with your provider.

BPC-157

BPC-157 has been studied mostly for gut protection and for tendon, ligament, muscle and bone healing in animals. A 2025 systematic review in sports medicine found 36 studies, of which 35 were preclinical and only one was clinical. FDA’s peptide evaluation also raised concerns about ingredient characterization and the risk of immune reactions. In October 2026, The Atlantic reported that much of the BPC-157 research traces back to a single lab in Croatia.

TB-500

TB-500 is a short fragment of thymosin beta-4. The human eye and wound studies often mentioned online used full-length thymosin beta-4, not the TB-500 fragment. According to the FDA PCAC evaluation, FDA did not identify clinical studies or human exposure data for TB-500 by any route.

KPV

KPV is a tiny three amino acid peptide derived from alpha-MSH. Mouse studies, including a 2008 study in Inflammatory Bowel Diseases, looked at its effect on intestinal inflammation. FDA did not identify human clinical studies for KPV, and the HHS policy covers only oral and topical forms.

MOTS-c

MOTS-c is a peptide encoded in mitochondrial DNA. Researchers have studied it in animals for metabolism and insulin sensitivity, including a 2025 study in Experimental & Molecular Medicine. FDA did not identify human data for MOTS-c given as a medication, and it is not a substitute for prescribed weight management therapy.

A note for athletes

BPC-157 and TB-500 appear on the World Anti-Doping Agency (WADA) prohibited list. If you compete in a tested sport, talk to your provider and your sport’s governing body before using any peptide. Nothing in this article is medical advice. Whether a compounded peptide is appropriate for you is a decision for you and your licensed provider.

What will the process look like at Bethelview Pharmacy?

Getting a compounded peptide will follow the same prescription-first path as our other compounded medications. Your provider decides whether a peptide is appropriate, and our pharmacist reviews the prescription, checks your other medications, and prepares a single-peptide product that meets the policy’s conditions.

  • Step 1: Provider evaluation. A licensed provider reviews your health history and goals and decides whether a compounded peptide fits your treatment plan. If you do not have a provider, our team can share information about providers through our contact page.
  • Step 2: Prescription to the pharmacy. Your provider sends a patient-specific prescription naming one peptide, its strength and an allowed form.
  • Step 3: Pharmacist review. Our pharmacist checks the prescription against the HHS policy, reviews your current medications for interactions, and contacts your provider with any questions.
  • Step 4: Compounding and quality checks. The peptide is prepared from a documented ingredient source with a certificate of analysis, following USP standards for sterile or nonsterile preparations.
  • Step 5: Counseling and pickup or delivery. You receive clear instructions on use, storage and how to report side effects. Pickup, local delivery in Forsyth County and shipping options are explained on our delivery and shipping page.

Will insurance cover compounded peptides?

Coverage for compounded peptides is unlikely because they are not FDA-approved drugs, and many plans exclude compounded medications. When peptide compounding launches, our team will share self-pay pricing with you before anything is prepared, so there are no surprises.

What about Georgia rules?

The HHS policy is federal, and it does not override state pharmacy law. Georgia pharmacies are licensed and overseen by the Georgia Board of Pharmacy. Bethelview Pharmacy will begin peptide compounding only when we have confirmed that it meets both the federal conditions and Georgia requirements. Because the HHS policy is still a draft, we will update this page if anything changes after the comment period closes.

Want to be among the first to hear when peptide compounding is available? Contact our pharmacist team.

Why Cumming families choose Bethelview Pharmacy for compounding

Bethelview Pharmacy is an independent, family-owned pharmacy at 2336 Atlanta Hwy in Cumming, GA, with an in-house compounding lab. Owner and pharmacist Kevin Patel, PharmD, RPh, brings more than 20 years of pharmacy experience and leads a team that knows patients by name, not by prescription number.

Our compounding work already spans hormone therapy, weight management, dermatology, pain management and more. Peptides will follow the same standards: documented ingredient sources, careful pharmacist review and direct coordination with your provider. You can see how we already approach this on our peptide compounding page.

When something new and widely discussed like peptides arrives, the questions matter as much as the medication. Our pharmacists take the time to explain what the policy allows, what the research does and does not show, and what to watch for, so you can make an informed decision with your provider. To learn why more local families are making the switch, read why Cumming families are moving to independent pharmacies.

Ready to ask about peptide compounding or get on our update list? Contact our pharmacist team.

Frequently asked questions

What is the new HHS peptide policy?

It is a draft enforcement discretion policy announced on October 28, 2026. HHS said it does not intend to take action against state-licensed pharmacies that compound six listed peptides, including BPC-157, TB-500, KPV and MOTS-c, when 10 conditions are met.

Are BPC-157, TB-500, KPV and MOTS-c FDA-approved?

No. None of these peptides is FDA-approved, and the HHS policy does not add them to the FDA’s 503A bulks list. Compounded peptides remain unapproved drugs that FDA has not reviewed for safety, effectiveness or quality.

Do I need a prescription for compounded peptides?

Yes. The HHS policy requires a valid, patient-specific prescription from a licensed provider for every compounded peptide. Pharmacies cannot sell these peptides without one.

Can a pharmacy combine BPC-157 and TB-500 in one product?

No. The policy allows only one active ingredient per compounded product. Blends and stacks that combine two or more peptides fall outside the policy’s conditions.

Can KPV be compounded as an injection?

No. Under Appendix B of the HHS policy, KPV is covered only in oral and topical forms. BPC-157 may be compounded as an injection, oral or topical form, while TB-500 and MOTS-c are limited to injections.

Is the HHS policy permanent?

No. It is a draft, public comments close on November 13, 2026, and HHS can revise or withdraw it. If it stays in place, it lasts until FDA finishes rulemaking on each peptide.

When will Bethelview Pharmacy start compounding peptides?

Bethelview Pharmacy is preparing now and will begin once federal and Georgia requirements are confirmed. Contact our team to be notified when peptide compounding is available.

Why not buy research peptides online instead?

“Research use only” peptides are not made for people, have no prescription or pharmacist oversight, and have shown quality problems in independent testing. FDA has also issued warning letters to online sellers marketing these products for human use.

Does insurance cover compounded peptides?

Most plans are unlikely to cover compounded peptides because they are not FDA-approved. Bethelview Pharmacy will share self-pay pricing before your medication is prepared.

Can athletes use BPC-157 or TB-500?

BPC-157 and TB-500 are on the World Anti-Doping Agency prohibited list. Athletes in tested sports should speak with their provider and governing body before using them.

Related reading

Kevin Patel, PharmD., RPh

Owner & Operator, Bethelview Pharmacy

At Bethelview Pharmacy, Kevin Patel, PharmD, RPh, brings over 20 years of pharmacy experience and personalized care to Cumming and Forsyth County. His mission is simple: provide attentive service, clear medication guidance, and genuine support with every prescription and pharmacy visit.

Have a Question?

Send us your enquiry and our team will be happy to help.

    Scroll to Top